Tręda, C.; Włodarczyk, A.; Pacholczyk, M.; Rutkowska, A.; Stoczyńska-Fidelus, E.; Kierasińska, A.; Rieske, P.
Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy. Int. J. Mol. Sci. 2023, 24, 4350.
https://doi.org/10.3390/ijms24054350
AMA Style
Tręda C, Włodarczyk A, Pacholczyk M, Rutkowska A, Stoczyńska-Fidelus E, Kierasińska A, Rieske P.
Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy. International Journal of Molecular Sciences. 2023; 24(5):4350.
https://doi.org/10.3390/ijms24054350
Chicago/Turabian Style
Tręda, Cezary, Aneta Włodarczyk, Marcin Pacholczyk, Adrianna Rutkowska, Ewelina Stoczyńska-Fidelus, Amelia Kierasińska, and Piotr Rieske.
2023. "Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy" International Journal of Molecular Sciences 24, no. 5: 4350.
https://doi.org/10.3390/ijms24054350
APA Style
Tręda, C., Włodarczyk, A., Pacholczyk, M., Rutkowska, A., Stoczyńska-Fidelus, E., Kierasińska, A., & Rieske, P.
(2023). Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy. International Journal of Molecular Sciences, 24(5), 4350.
https://doi.org/10.3390/ijms24054350